Gene Expression Profile–Based Test to Predict Melanoma Sentinel Node Status
JAMA Surgery · 2025
DOI: 10.1001/jamasurg.2025.4399 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA Surgery, 2025. Verfasst von Tina J Hieken und 21 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Surgery and Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota. Hauptthemen laut MEDLINE: Gene Expression Profiling, Melanoma, Sentinel Lymph Node, Sentinel Lymph Node Biopsy. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Importance Contemporary guidelines recommend sentinel lymph node biopsy (SLNB) for patients with melanoma with predicted risk of SLN metastasis greater than 10% and consideration of SLNB when the risk is 5% to 10%. A gene expression profile (GEP)–based test that can accurately identify patients with a low risk of SLN metastasis would refine selection for SLNB.
Objective
To establish the predictive capability of the combined clinicopathological factors and GEP (CP-GEP) test to identify patients with primary cutaneous melanoma who can safely forgo SLNB and to investigate the prognostic value of CP-GEP regarding the outcome in patients with cutaneous melanoma after a negative SLNB (not reported herein). Design, Setting, and Participants This prognostic study was conducted from September 2021 to June 2024 at 9 academic medical centers with experienced melanoma surgeons. Included were patients with biopsy-proven invasive cutaneous melanoma with T1 to T3 tumors and clinically negative regional LNs. All patients were deemed candidates for SLNB using standard clinical criteria. GEP was performed on formalin-fixed, paraffin-embedded tissue from the primary melanoma biopsy. Analyses were performed from December 2024 to August 2025.
Intervention
CP-GEP testing to determine risk of having a positive SLNB in patients with T1 to T3 cutaneous melanoma who were considered appropriate candidates for the procedure based on standard clinical parameters. Main Outcomes and Measures CP-GEP results were reported as low risk or high risk; the primary outcome measure was negative predictive value (NPV) in low-risk cases. Analyses included NPV assessment by tumor (T) subcategory, primary site, and age.
Results
A total of 1761 patients (median [IQR] age, 64 [53-72] years; 997 male [56.6%]) underwent SLNB (310 [17.6%] SLN positive) and had a successful CP-GEP test; GEP was successful in 97.7% of samples. A total of 651 patients (37.0%) were considered low risk by CP-GEP. Among low-risk cases, 46 (7.1%) were SLN positive, and NPV was 92.9% (95% CI, 90.7%-94.8%). High-risk cases had a 23.8% (264 of 1110) SLN-positive rate. The percentage of cases with low-risk CP-GEP declined with increasing T category (T1 = 346 of 507 [68.2%]; T2 = 295 of 897 [32.9%]; T3 = 10 of 357 [2.8%]). CP-GEP results were consistent in discriminating SLN-positive rates across primary sites, histologic subtypes, and mitotic count categories. In 2 large subsets, clinical stage IB (n = 1187) and patients 65 years and older (n = 832), 6.5% (95% CI, 4.6%-8.8%) of low-risk clinical stage IB cases and 6.6% (95% CI, 4.2%-9.7%) of all low-risk cases in patients 65 years and older were SLN positive vs 18.3% (95% CI, 15.3%-21.6%) and 20.3% (95% CI, 16.8%-24.2%) for high-risk cases, respectively. Conclusions and Relevance In this multicenter, prospective, blinded, prognostic study, the CP-GEP test reliably identified patients with melanoma with less than 10% SLN metastasis risk. SLN metastasis rates were approximately 3-fold greater for high-risk vs low-risk CP-GEP cases. In appropriately selected patients, the CP-GEP test may add value for shared patient-surgeon decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Departments of Surgery and Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota.
- Hiram C. Polk Jr, MD Department of Surgery, The University of Louisville School of Medicine, Louisville, Kentucky.
- Departments of Surgery, Pathology and Dermatology, The University of Michigan Rogel Cancer Center, Ann Arbor.
- Departments of Surgery and Dermatology, The Huntsman Cancer Institute, University of Utah, Salt Lake City.
- Department of Surgery, Rush University, Chicago, Illinois.
- Department of Surgery and Pathology, The University of Kentucky, Lexington.
Förderung
- NCI NIH HHS
Zitieren
APA
Hieken, T. J., Egger, M. E., Angeles, C. V., Hyngstrom, J. R., Burke, E. E., Lowe, M. C., Beasley, G. M., Bartlett, E. K., Bresler, S. C., Harms, K. L., Zager, J. S., Lehman, J. S., Wasif, N., Bagaria, S. P., McMasters, K. M., Wada, D. A., Pandalai, P., Delman, K. A., Lee, J., …, & Sondak, V. K. (2025). Gene Expression Profile–Based Test to Predict Melanoma Sentinel Node Status. JAMA Surgery. https://doi.org/10.1001/jamasurg.2025.4399
Vancouver
Hieken TJ, Egger ME, Angeles CV, Hyngstrom JR, Burke EE, Lowe MC, et al. Gene Expression Profile–Based Test to Predict Melanoma Sentinel Node Status. JAMA Surgery. 2025. doi:10.1001/jamasurg.2025.4399
BibTeX
@article{Hieken2025,
author = {Hieken, Tina J and Egger, Michael E and Angeles, Christina V and Hyngstrom, John R and Burke, Erin E and Lowe, Michael C and Beasley, Georgia M and Bartlett, Edmund K and Bresler, Scott C and Harms, Kelly L and Zager, Jonathan S and Lehman, Julia S and Wasif, Nabil and Bagaria, Sanjay P and McMasters, Kelly M and Wada, David A and Pandalai, Prakash and Delman, Keith A and Lee, Jay and Busam, Klaus J and Messina, Jane L and Sondak, Vernon K},
title = {Gene Expression Profile–Based Test to Predict Melanoma Sentinel Node Status},
journal = {JAMA Surgery},
year = {2025},
doi = {10.1001/jamasurg.2025.4399}
}
EUVIMED